Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart

Journal of the American College of Cardiology

Volumn 40, Issue 5, 2002, Pages 998-1005

  Ogita, Hisakazu ^a   Node, Koichi ^a   Asanuma, Hiroshi ^a   Sanada, Shoji ^a   Liao, Yulin ^a   Takashima, Seiji ^a   Asakura, Masanori ^a   Mori, Hidezo ^c   Shinozaki, Yoshiro ^b   Hori, Masatsugu ^a   Kitakaze, Masafumi ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHARYBDOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; CORONARY RISK; DOG; DRUG INFUSION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; CHARYBDOTOXIN; DOGS; ENZYME INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEROXIDASE; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RALOXIFENE; REPERFUSION INJURY; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0037019577     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02056-9     Document Type: Article

References (33)

1. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year results from the Nurses' Health study
2. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17β-estradiol: Role of nitric oxide and calcium-activated potassium channels
3. + channels in coronary vasodilation induced by 17β-estradiol in ischemic heart failure
4. Update on cancer control in women
5. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: Prospective cohort study and review of the literature
6. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
7. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
8. Raloxifene and estrogen: Comparative bone-remodeling kinetics
9. Effects of raloxifene on serum lipids and coagulation factors in healthy post-menopausal women
10. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
11. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
12. Mitogen-activated protein kinase pathways
13. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion
14. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia
15. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart
16. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart
17. Plasma nitric oxide end products are increased in the ischemic canine heart
18. + channels regulates coronary blood flow in ischemic myocardium
19. New nonradioactive microspheres and more sensitive x-ray fluorescence to measure regional blood flow
20. Nifedipine limits infarct size via NO-dependent mechanisms in dogs
21. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium
22. Antineutrophil and myocardial protecting action of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs
23. 2+ current: Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation
24. Endogenous nitric oxide is implicated in the regulation of lipolysis through antioxidant-related effect
25. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase
26. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
27. Role of mitogen-activated protein kinases in ischemia and reperfusion injury: The good and the bad
28. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart
29. p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function
30. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38
31. Hypertonic saline inhibits neutrophil (PMN) priming via attenuation of p38 MAPK signaling
32. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue
33. Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury